Polycystic ovary syndrome is a very complex disease, and its pathophysiological state is also progressing, with a Kaohsiung hypoestrogenic state, unstable or immature function of the endocrine regulatory axis, predisposing to follicular dysplasia or long follicular phase, or months or longer anovulation, and scanty menstruation, thus affecting conception. Literature reports in recent years have shown that patients, whether obese or not, have varying degrees of insulin resistance (IR), i.e., insulin malfunction and metabolic hyperinsulinemia. Hyperinsulinism can stimulate ovarian androgen synthase and increase ovarian androgen synthesis, as well as alter lipoprotein and cholesterol metabolism to produce hyperlipidemia, leading to atherosclerosis causing the occurrence of cardiovascular and cerebrovascular diseases, and also has the potential risk of endometrial cancer, breast cancer, diabetes and other diseases. Therefore, active treatment of PCOS is important for infertility and reducing the occurrence of complications of PCOS. Daine-35 is a combined oral contraceptive (COC) that competes for dihydrotestosterone receptors, inhibits 5α-reductase activity, and suppresses gonadotropin secretion to reduce ovarian androgen production, and is one of the common treatments for PCOS. However, some scholars have observed that OC does not significantly improve the insulin resistance status of PCOS while reducing androgens, and does not improve or even worsen the disorders of lipid metabolism associated with PCOS. Metformin can play the role of systemic insulin sensitization, thus improving insulin resistance and hyperinsulinemia, reducing the activity of cytochrome P450C17a in ovaries and adrenal glands caused by the latter, thus reducing androgen synthesis, restoring normal LH and FSH secretion, and promoting the restoration of ovulatory cycle, which has become one of the drugs for the treatment of PCOS in recent years. Many studies suggest that metformin can also improve insulin resistance by reducing plasma adipocytokines and inflammatory factors. However, the disadvantage of clinical use of metformin is that some patients cannot resume normal menstruation. Chinese and Western medicine have their own strengths and weaknesses in the treatment of polycystic. Clinically, some patients can better develop follicles and ovulate when using Chinese medicine alone, and their efficiency is not weaker than ovulation drugs. Of course Chinese herbal medicine, when combined with related drugs such as improving ovarian sensitivity, improving hyperinsulinemia or refusal status, can significantly improve clinical efficacy and shorten the treatment cycle.